Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACEDUCT Trial
2023-503209-13-00Phase 2Completed
- Sponsor
- RCSI University of Medicine and Health Sciences
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial in patent ductus arteriosus (PDA) and bronchopulmonary dysplasia (BPD) comparing Ibuprofen alone with Ibuprofen + paracetamol (2 arms). Primary endpoint: Composite of pre-discharge mortality or any grade bronchopulmonary dysplasia. Started Jul 2023; status: completed.
02
Drugs
acetaminophenibuprofen
03
Conditions
patent ductus arteriosus (PDA)bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2023-503209-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503209-13-00.